BlackRock Investment Management’s Fate Therapeutics FATE Stock Holding History

BlackRock Investment Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$12K	Hold	4,596	–	–	﹤0.01%	3537
2016 Q3	$14K	Buy	4,596 +269	+6%	+$653	﹤0.01%	3463
2016 Q2	$7K	Hold	4,327	–	–	﹤0.01%	3757
2016 Q1	$8K	Hold	4,327	–	–	﹤0.01%	3692
2015 Q4	$15K	Hold	4,327	–	–	﹤0.01%	3522
2015 Q3	$23K	Buy	4,327 +242	+6%	+$1.65K	﹤0.01%	3394
2015 Q2	$26K	Buy	4,085 +1,906	+87%	+$11.4K	﹤0.01%	3374
2015 Q1	$11K	Sell	2,179 -69	-3%	-$342	﹤0.01%	3613
2014 Q4	$11K	Hold	2,248	–	–	﹤0.01%	3636
2014 Q3	$11K	Buy	2,248 +175	+8%	+$1.01K	﹤0.01%	3626
2014 Q2	$13K	Buy	+2,073	New	+$14.6K	﹤0.01%	3537

Other funds holding FATE

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock Investment Management's FATE Position: Q4 2016 in Review

BlackRock Investment Management held its Fate Therapeutics (FATE) position steady in Q4 2016 at 4,596 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #3537.

BlackRock Investment Management first reported a position in FATE in Q2 2014 and has held it in 11 quarters since. The position peaked at $26K in Q2 2015. 37 funds tracked by Wall St. Rank hold FATE as of Q4 2016.

BlackRock Investment Management held 4,596 shares of Fate Therapeutics worth $12K as of Q4 2016.
BlackRock Investment Management left its Fate Therapeutics share count unchanged in Q4 2016.
Fate Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3537 holding.
BlackRock Investment Management first reported a position in Fate Therapeutics in Q2 2014 and has held it in 11 quarters since.
BlackRock Investment Management's Fate Therapeutics position peaked at $26K in Q2 2015.
37 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.